Block Grant R21NS060262

This $427,625 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to the University of Washington aims to develop and optimize two novel blood-based biomarker assays to improve clinical diagnosis and differential diagnosis of Parkinson's disease (PD) and multiple system atrophy (MSA). The key products and services to be delivered under this 2-year grant include: Further development and optimization of a flow cytometry-based assay (APOGEE) to directly quantify...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...

Duke University's Office of Research Administration received a $1.8M Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded on May 11, 2026, with completion targeted for April 30, 2029. The research project investigates LRRK2 (Leucine-Rich Repeat Kinase 2) signaling pathways and their role in Parkinson's disease (PD) and dementia progression....

This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $320,143 to Mayo Clinic to assess the diagnostic and disease biomarker utility of blood plasma measures in patients with atypical Alzheimer's disease (AD). The 2-year project aims to determine if plasma biomarkers can differentiate atypical AD patients from healthy controls and other clinical syndromes, as well as evaluate if the plasma biomarkers correlate with clinical...

This National Science Foundation project grant of $156,238 awarded on January 1, 2023 will fund research at Colorado State University to develop analytical tools combining heterogeneous genetic and molecular data sources to identify genetic modifiers of Parkinson's disease. Under the Mathematical and Physical Sciences program (CFDA 47.049), the researchers will use a hierarchical three-group mixture model to probabilistically model genes as null, deleterious, or beneficial based on genome-wide...

This Project Grant award for $1,386,000.00 was provided by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant supports a comprehensive investigation into the mechanisms underlying the neurotoxic spread of alpha-synuclein protein from the gut to the brain in Parkinson's disease. The research aims to generate new gut-to-brain transmission models in C. elegans to map the spread of alpha-synuclein pathology and...

This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to establish the role of alpha-synuclein-mediated membrane permeabilization in the spread of alpha-synuclein aggregates related to Parkinson's disease and related dementias. The $406,260 award to Purdue University will leverage fluorescence lifetime imaging microscopy...

The National Institute on Aging (NIA) awarded a $459,250 Project Grant (CFDA 93.866 - Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate and validate the use of dried blood spot (DBS) samples for measuring Alzheimer's disease (AD) biomarkers. The key objectives are to: 1) optimize fingerstick collection methods and validate assays for three key AD biomarkers (pTau217, GFAP, and NFL) in DBS samples; 2) establish if DBS...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...

Federal Project Grant Award Summary CND Life Sciences, Inc. received a $1,276,662 Project Grant from the National Institute of Neurological Disorders and Stroke under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, awarded September 5, 2025, with completion targeted for August 31, 2028. This direct-to-Phase II Small Business Innovation Research (SBIR) award funds development and validation of the SYN-ONE Test, a minimally invasive...